Case Presentation 31 year-old man with increased blast count

Slides:



Advertisements
Similar presentations
Hematopathology Lab December 12, Case 1 . Normal Peripheral Blood Smear.
Advertisements

Hematology Case # 1 History of Present Illness
Hematology RBC/WBC Case Studies
HAEMATOLOGY MODULE: LYMPHOMA Adult Medical-Surgical Nursing.
Acute leukemia Mohammed Al-matrafi.
A 35 year old woman presents with increasing fatigue, lethargy, and muscle weakness. Her CBC reveals decreased numbers of erythrocytes, leukocytes, and.
MANTLE CELL Lymphoma (WITH EMPHASIS ON THE gi TRACT)
Proposed WHO Classification of Lymphoid neoplasm
ECSI case Fall 2014 Andrea M. Sheehan, MD Associate Professor of Pathology & Immunology Baylor College of Medicine.
By Taylor, Lanny, and Alex. What is it?  Leukemia is an abnormal rise in the number of white blood cells. The white blood cells crowd out other blood.
Chronic lymphocytic leukemia (1)
Chronic Lymphocytic Leukemia (CLL) DEFINITION CLL is a neoplastic disease characterized by proliferation and accumulation (blood, marrow and lymphoid.
Chapter 17 Chronic Leukemias.
Chronic Lymphocytic Leukemia. Definition Clonal B cell malignancy. Progressive accumulation of long lived mature lymphocytes. Increase in anti-apoptotic.
Chronic Leukemia Dr. Rania Alhady Chronic Lymphocytic leukemia (CLL):
Host Defense Clinical and Experimental Immunologic Assays II Domenick Kennedy Dept. Microbiology and Immunology
NYU Medicine Grand Rounds Clinical Vignette Maryann Kwa, MD PGY-2 January 12, 2011 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Lymphoma. ALLMMCLLLymphomas Hematopoietic stem cell Neutrophils Eosinophils Basophils Monocytes Platelets Red cells Myeloid progenitor Myeloproliferative.
O THER MALIGNANT LYMPHOPROLIFERATIVE DISORDERS The lymphomas and plasma cell problems.
Oncology Slide Review LaJuan Chambers, MD. 16 yo young man with fatigue, pallor and low-grade fever for 2 weeks On exam, spleen palpated 8cm below left.
ICCS e-Newsletter CSI Spring 2013 David A Westerman, MBBS FRACP FRCPA Department of Pathology Peter MacCallum Cancer Centre Melbourne, Australia.
MedPix Medical Image Database COW - Case of the Week Case Contributor: Caitlin M Nickens Affiliation: Uniformed Services University.
The acute Leukemias are clonal hematopoietic malignant disease that arise from the malignant T r a n s f o r m a t i o n of an early Hematopoietic stem.
T-cell/histiocyte-rich large B cell lymphoma Monirath Hav, MD, PhD fellow Pathology Department Ghent University Hospital.
Acute Myeloid Leukemias Diagnosis in The Light of WHO Revisions And Correlation With Risk Adaptive Management ; Case Discussions Dr. Rania Medhat Seliem.
Chronic Leukemias. CMLCML CLLCLL CML A clonal disease results from an acquired genetic change in a pluri-potential hemopoietic stem cell within the BM.
Case Study MICR Hematology Spring, 2011 Case # 5 Hee Jin Kim, Hooman Nikizad and Arthur Omuro.
Myeloproliferative Disorders (MPDs)
Leukemia.
Chronic leukemia 1. Chronic Lymphocytic leukemia (CLL) * Definition: Chronic neoplastic disorder characterized by accumulation of small mature-looking.
Pei Lin Professor of Pathology Department of Hematopathology
ZHIHONG HU, MD, PhD Fellow, Department of Hematopahtology
APPROACH TO LYMPHOID MALIGNANCIES. Patient Evaluation of ALL Careful history and PE CBC Chemistry studies Bone marrow biopsy Lumbar puncture.
Fellow, Dept of Hematopathology 1515 Holcombe Blvd, Unit 072
CHRONIC LEUKEMIA Dr. Hayam Hebah Associate professor of Internal Medicine AL Maarefa College.
Hodgkin’s Lymphoma Hodgkin’s Lymphoma Disease in which malignant (cancer) cells form in the lymph system Type of cancer that develops in.
TCR gamma/delta LGL proliferation causing recurrent episodes of neutropenia proceeding into fatal hepatosplenic T-cell lymphoma in an adolescent girl 5.
Single-Agent Lenalidomide Induces Complete Remission of Acute Myeloid Leukemia in Patients with Isolated Trisomy 13 Fehniger TA et al. Blood 2009;113(5):
Future Directions in ALK Negative Anaplastic Large Cell Lymphoma
..  Neoplastic proliferation of small mature appearing  lymphocytes and account 25% of leukemia  It is rare before 40 years of age, the median age.
B-ALL as the Initial Presentation of a Hematopoietic Neoplasm with t(8;22)/BCR-FGFR1 The University of Texas MD Anderson Cancer Center Department of Hematopathology.
Hematopoetic Cancers. Hematopoesis Leukemia New diagnoses each year in the US: 40, 800 Adults 3,500 Children 21,840 died of leukemia in 2010.
Acute Leukemia Kristine Krafts, M.D..
Case report Sudden blastic transformation in patient with chronic myeloid leukemia treated with imatinib mesylate Mehrdad Payandeh,MD Hematology, Medical.
HANDOUT 3 RARITIES.
Case 297 Guilin Tang and Sa A. Wang Department of Hematopathology UT MD Anderson Cancer Center.
Leukemia. What is Leukemia?  Leukemia is a cancer of the blood  It is the most common type of blood cancer beginning in the bone marrow where abnormal.
Chronic leukemias أ. م. د. محمد شنين علي العبادي معاون عميد كلية الطب / جامعة كربلاء ورئيس فرع الامراض والطب العدلي M. B. Ch. B. & F. I. C. P.(Hematopathology)
Case 251: Clinical Information Raymond E Felgar, MD, PhD University of Pittsburgh, Pittsburgh, PA 45-year-old man with recent history of shingles, night.
Case 255 Elizabeth Courville, MD Robert Hasserjian, MD Massachusetts General Hospital Society for Hematopathology/European Association for Haematopathology.
Society for Hematopathology/European Association for Haematopathology 2013 Case Number 208 Erika Moore, MD; Darshan Roy, MD; Patti Cohen, MD; Adam Bagg,
SH/EAHP Workshop 2013 Case 93 Winnie Wu, M.D. Sheeja Pullarkat, M.D.
Case 316 Ryan Johnson, MD; Athena Cherry, PhD; Dita Gratzinger, MD, PhD Stanford University Medical Center SH-EAHP October 24, 2013.
CASE 411 Jose Gonzalez-Berjon, MD & Tariq Muzzafar, MD UT M.D. Anderson Cancer Center.
CP Case Conference Aplastic Anemia 1/27/12 Laura Walters.
Patient history 70 year-old male with macrocytic anemia for 10 years, became transfusion dependent. Splenectomy for refractory anemia: 670gm B12, folate,
Acute Leukemia Kristine Krafts, M.D..
CASE OF THE MONTH Dr Narender Tejwani Consultant ( Hematopathologist)
CASE SUBMISSION 2016 EAHP BM Workshop
Acute myeloid leukemia
18th Meeting of the European Association for Hematopathology
PRIMARY CUTANEOUS γδ T-CELL LYMPHOMA:REPORT OF A RARE ENTITY
11 th lecture Chronic myeloid leukaemia By DR Fatehia Awny Faculty of Health Science Beirut Arab University
Immunosuppressive related indolent
CHRONIC MYELOID LEUKEMIA (CML)
Case Study ….
Lymphoid Preponderance and the Absence of Basophilia
Case study.
Neoplastic disorder.
Presentation transcript:

Case Presentation 31 year-old man with increased blast count   Mariko Yabe, MD, PhD Hematopathology Fellow University of Texas MD Anderson Cancer Center January 22, 2016

Clinical History 31 year-old man Fever, chills, night sweat for 1 week PMH Crohn’s disease (Treated with 6-Mercaptopurine,Mesalamine) Physical exam Jaundice Splenomegaly

CBC WBC 7.2 x 109/L (Meta 1, Neutro 54, Lymph 23, Mono 22) Hgb 8.7 g/dL MCV 94 fL PLT 75 x 109/L Chemistry T-Bil 2.1 mg/dL (ref: 0.0-1.0) ALP 240 IU/L (ref: 58-237) LDH 3163 IU/L (ref: 313-618) AST 67 IU/L (ref: 10-40) ALT 87 IU/L (ref: 15-46) B2M 3.8 mg/L (ref: 0.7-1.8)

BM aspirate Giemsa (x 500)

BM diff Blasts 34 % (0-5) Progranulocytes 0 % (2-8) Myelocytes 11 % (5-20) Metamyelocytes 9 % (13-32) Granulocytes 11 % (7-30) Eosinophils 2 % (0-4) Lymphocytes 7 % (3-17) Plasma cells 2 % (0-2) Monocytes 2 % (0-5) Pronormoblasts 1 % (1-8) Normoblasts 22 % (7-32) M:E Ratio 1.4 (3-4)

BM core Bx H&E (x 100)

CD3

CD4

CD8

TCRγ

βF1

Other Immunohistochemistry TIA-1 Negative Granzyme B Negative EBER Negative

Flow cytometry SSC CD4 CD8 CD45

CD2 CD7 CD5 CD26 TCR γδ CD56 CD57 TCR αβ

Cytogenetics Molecular 46,X,-Y,i(7)(q10),+8[6]/ 46,X,-Y,i(7)(q10),+8,t(9;20)(q13;q11.2)[1]/ 46,XY[13] v Molecular Monoclonal TCR gamma rearrangement detected

Proposed Diagnosis Hepatosplenic T-cell Lymphoma

Discussion HSTCL can be a mimic of T lymphoblastic leukemia/lymphoma Subset of HSTCL patients has underlying immune disorders Prognostic factors

Discussion HSTCL can be a mimic of T lymphoblastic leukemia/lymphoma Subset of HSTCL patients has underlying immune disorders Prognostic factors

Hepatosplenic T-cell lymphoma Rare and aggressive extranodal T-cell lymphoma, usually seen in adolescents and young adults Virtually all cases show bone marrow involvement Lymphoma cells typically show CD2+/CD3+/CD4-/CD5-/CD7+/CD8-/CD56+/CD57- TIA-1+/Granzyme B ±

Morphologic Spectrum Small 18% Intermediate 43% Large 14% Blastoid 25% Yabe M, et al. Am J Surg pathol. 2016 in press

Lymphoma cell/prolymphocyte-like morphology T lymphoblastic leukemia/lymphoma Lymphoma cell/prolymphocyte-like morphology Blastoid Hepatosplenic T-cell lymphoma

Take-home messages (1) Virtually all cases of hepatosplenic T-cell lymphoma show bone marrow involvement Subset of cases has blastoid morphology -> HSTCL could be misdiagnosed with T lymphoblastic leukemia/lymphoma

Discussion HSTCL can be a mimic of T lymphoblastic leukemia/lymphoma Subset of HSTCL patients has underlying immune disorders Prognostic factors

HSTCL arising in patients with underlying immune disorders Subset of patients (~20%) with HSTCL have a history of immune disorders In our multi-institutional study 29 HSTCL patients (Jan 2000-Dec 2015) 7 patients had underlying immune disorders (24%)

7 Patients at MD Anderson Time to develop HSTCL Case # Gender Age Underlying disease From immune disorder (years) From drug exposure (years) 1 M 21 CD 13 NA 2 49 UC 5 3 31 4 18 38 16 6 51 RA 7 F 72 Yabe M, et al. USCAP 2016

No underlying immune disorders Review of the literature identified additional 60 patients with HSTCL arising in immune disorders Underlying immune disorders No underlying immune disorders   n= 67 n= 22 p value Age, median (range) 31.5 7-79 32.5 4 - 82 0.8362 Gender Male 56 84% 13 59% Female 11 16% 9 41% 0.0359 Underlying immune disorders Crohn's disease 40 Ulcerative colitis 7 Rheumatoid arthritis 6 Post renal transplant 5 Post liver transplant 2 Post allogeneic stem cell transplant 1 Churg Strauss syndrome Sjogren syndrome Systemic lupus erythematosus Psoriasis Hodgkin lymphoma, treated ALPS, Evans syndrome Yabe M, et al. USCAP 2016

Medication of Patients with Underlying Immune Disorders who Developed HSTCL Immunosupressive/cytotoxic drugs % Azathioprine 46% 6-Mercaptopurine 33% Cyclosporine 13% Methotrexate 8% Tumor necrosis factor-α inhibitors Infliximab 44% Adalimumab Etanercept 2% Miscellaneous Steroids 67% Mesalazine or Sulfasalazine 39% Yabe M, et al. USCAP 2016

90% 49% 41% 2% 8% Neither Summary of Medication immunosuppressive drugs TNF-α inhibitors 90% 49% 41% 2% 8% Neither -> More than 50% patients didn’t receive TNF-α inhibitors

Comparison of Cytogenetic Analysis i(7q) significantly increased Underlying immune disorders No underlying p value i(7q) 19/26 73% 6/19 32% 0.0076 Trisomy 8   9/26 35% 7/19 37% 1.0000 i(7q) significantly increased No increase in trisomy 8 Yabe M, et al. USCAP 2016

Comparison of Immunophenotype Underlying immune disorders No underlying P-value Immunophenotype (% positive cases) CD2 28/28 100% 20/22 91% 0.1886 CD3 32/32 21/22 95% 0.4074 CD4 3/31 10% 0/22 0% 0.2576 CD5 2/27 7% 1/22 5% 1.0000 CD7 25/27 93% 22/22 0.4949 CD8 7/29 24% 4/28 18% 0.5045 CD56 26/28 14/22 64% 0.0145 CD57 0/15 1/17 6% TIA-1 12/17 71% 20/21 0.0712 Granzyme B 2/13 15% 9/20 45% 0.1322 EBER 1/16 0/19 0.4571 Yabe M, et al. USCAP 2016

Take-home messages (2) Subset of the patients have underlying immune disorders, most frequently Crohn’s disease These patients show prominent male predominance, frequent expression of CD56, and often carry i(7q) Despite the underlying immune disorders, EBER is negative in most of the cases

Discussion HSTCL can be a mimic of T lymphoblastic leukemia/lymphoma Subset of HSTCL patients has underlying immune disorders Prognostic factors

Clinical course of this 31 year-old patient After the diagnosis of HSTCL, he received Hyper-CVAD. A day #21 bone marrow aspiration showed persistent HSTCL. He received additional 2 courses of Hyper-CVAD (total 3 courses) Despite the chemotherapy, his splenomegaly and hepatomegaly was not controlled, and the clinical course was also complicated with multiple infections. He died 11 weeks after the diagnosis of HSTCL.

Adverse prognostic factors Outcomes (n= 27) OS Adverse prognostic factors Elevated serum bilirubin Expression of αβ TCR Presence of trisomy 8 Yabe M, et al. Am J Surg Pathol. 2016 in press

Take-home messages (3) Prognosis is poor, but some patients achieve long-term survival Adverse prognostic factors are Elevated serum bilirubin Expression of αβ TCR Presence of trisomy 8 Long term survival could be achieved with allogeneic Stem Cell Transplant

Thank you